Amita Patel, M.D., adult and geriatric psychiatrist at Dayton Psychiatric Associates, and Joel G. Winner, M.D., medical director of AssureRx, will present their scientific and clinical report titled “Using Pharmacogenomic Testing in Clinical Practice” at noon HAST on Sunday, May 15. In addition, Aida Mihajlovic, M.D., assistant professor, Department of Psychiatry, University of Illinois at Chicago and private practice psychiatrist, will present initial findings from a retrospective study of outcomes in outpatients with major depressive disorder (MDD) in a staff model HMO at 10 a.m. HAST on Tuesday, May 17.
A GeneSightRx testing program will also be implemented during the conference for the first 200 physicians who visit AssureRx’s booth. The program will provide physicians with the opportunity to experience the simplicity and ease of use in gathering the information necessary to perform the GeneSightRx pharmacogenetic test.
“The presentations and other activities at the APA conference will demonstrate the benefits and simplicity of incorporating the use of GeneSightRx into clinical practice,” said John A. Bellano, senior vice president, sales and commercial programs of AssureRx. “Physicians will have the opportunity to hear and experience how, from a simple cheek swab, the GeneSightRx technology can measure and analyze clinically important genetic variants that determine how an individual patient’s unique genetic make-up affects his or her ability to tolerate or effectively respond to psychotropic medications.”
GeneSight is a laboratory developed pharmacogenomic test that uses cutting edge technology to measure and analyze clinically important genomic variants in the treatment of psychiatric disorders. The results of the GeneSight report can help a clinician understand the way a patient’s unique genomic makeup may affect certain psychiatric drugs. The analysis is based on pharmacogenomics, the study of genomic factors that influence an individual’s response to drug treatments, FDA approved manufacturer’s drug labels, peer-reviewed scientific and clinical publications, and proven drug pharmacology. Quick turnaround time, combined with a customized report of the patient’s genomic makeup, clinical experience and other factors can help a physician make personalized drug treatment choices for each patient.
About AssureRx Health, Inc.
AssureRx Health, Inc. is a personalized medicine company that specializes in pharmacogenomics dedicated to helping physicians determine the right drug for individual patients suffering from neuropsychiatric and other disorders. The company was founded to commercialize industry-leading personalized medicine technology for neuropsychiatric disorders. Mayo Clinic and Cincinnati Children’s Hospital Medical Center are equity holders and technology collaborators.
SVP, Sales & Commercial Programs
AssureRx Health, Inc.